"The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE).
Last reviewed on RxList: 5/21/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional VPRIV Information
Report Problems to the Food and Drug Administration
Find out what women really need.